{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T14:20:44Z","timestamp":1720016444116},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain Research"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.brainres.2018.06.009","type":"journal-article","created":{"date-parts":[[2018,6,11]],"date-time":"2018-06-11T15:34:21Z","timestamp":1528731261000},"page":"21-33","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Intravenous immunoglobulin ameliorates motor and cognitive deficits and neuropathology in R6\/2 mouse model of Huntington\u2019s disease by decreasing mutant huntingtin protein level and normalizing NF-\u03baB signaling pathway"],"prefix":"10.1016","volume":"1697","author":[{"given":"Shu-ying","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-lin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang-meng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quan-xiu","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui-tian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.brainres.2018.06.009_b0005","doi-asserted-by":"crossref","unstructured":"1993. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. The Huntington\u2019s Disease Collaborative Research Group. Cell. 72, 971\u2013983.","DOI":"10.1016\/0092-8674(93)90585-E"},{"key":"10.1016\/j.brainres.2018.06.009_b0010","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.imbio.2011.07.023","article-title":"Complement activation as a biomarker for Alzheimer\u2019s disease","volume":"217","author":"Aiyaz","year":"2012","journal-title":"Immunobiology"},{"key":"10.1016\/j.brainres.2018.06.009_b0015","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.freeradbiomed.2013.04.017","article-title":"Role of oxidative DNA damage in mitochondrial dysfunction and Huntington\u2019s disease pathogenesis","volume":"62","author":"Ayala-Pena","year":"2013","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.brainres.2018.06.009_b0020","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1212\/01.wnl.0000334276.09729.0e","article-title":"Weight loss in Huntington disease increases with higher CAG repeat number","volume":"71","author":"Aziz","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.brainres.2018.06.009_b0025","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1182\/blood.V74.1.326.326","article-title":"High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance","volume":"74","author":"Basta","year":"1989","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.brainres.2018.06.009_b0030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/cei.1996.104.s1.21","article-title":"Modulation of complement-mediated immune damage by intravenous immune globulin","volume":"104","author":"Basta","year":"1996","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.brainres.2018.06.009_b0035","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1016\/j.molimm.2008.07.012","article-title":"Ambivalent effect of immunoglobulins on the complement system: activation versus inhibition","volume":"45","author":"Basta","year":"2008","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.brainres.2018.06.009_b0040","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.neuron.2016.10.064","article-title":"Phosphodiesterase 10A inhibition improves cortico-basal ganglia function in Huntington\u2019s disease models","volume":"92","author":"Beaumont","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.brainres.2018.06.009_b0045","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1750-3639.1999.tb00216.x","article-title":"Oxidative stress in Huntington\u2019s disease","volume":"9","author":"Browne","year":"1999","journal-title":"Brain Pathol."},{"key":"10.1016\/j.brainres.2018.06.009_b0050","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.bbi.2014.09.011","article-title":"Plasma inflammatory biomarkers for Huntington\u2019s disease patients and mouse model","volume":"44","author":"Chang","year":"2015","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.brainres.2018.06.009_b0055","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1021\/acschemneuro.6b00042","article-title":"The immune system and neuroinflammation as potential sources of blood-based biomarkers for Alzheimer\u2019s disease, Parkinson\u2019s disease, and Huntington\u2019s disease","volume":"7","author":"Clark","year":"2016","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.brainres.2018.06.009_b0060","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.neuron.2010.12.035","article-title":"Huntington\u2019s disease: can mice lead the way to treatment?","volume":"69","author":"Crook","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/j.brainres.2018.06.009_b0065","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nn.3668","article-title":"Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors","volume":"17","author":"Crotti","year":"2014","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.brainres.2018.06.009_b0070","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1152\/jn.00762.2011","article-title":"A critical window of CAG repeat-length correlates with phenotype severity in the R6\/2 mouse model of Huntington\u2019s disease","volume":"107","author":"Cummings","year":"2012","journal-title":"J. Neurophysiol."},{"issue":"Suppl. 1","key":"10.1016\/j.brainres.2018.06.009_b0075","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1007\/s10875-014-0024-5","article-title":"Mechanistic effects of IVIg in neuroinflammatory diseases: conclusions based on clinicopathologic correlations","volume":"34","author":"Dalakas","year":"2014","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.brainres.2018.06.009_b0080","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1021\/pr0700753","article-title":"Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates","volume":"6","author":"Dalrymple","year":"2007","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.brainres.2018.06.009_b0085","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","article-title":"Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain","volume":"277","author":"DiFiglia","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.brainres.2018.06.009_b0090","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1136\/jnnp.2003.033399","article-title":"Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer\u2019s disease","volume":"75","author":"Dodel","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.brainres.2018.06.009_b0095","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.nbd.2014.08.021","article-title":"The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington\u2019s disease","volume":"73","author":"Doria","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.brainres.2018.06.009_b0100","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1523\/JNEUROSCI.22-05-01592.2002","article-title":"Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington\u2019s disease","volume":"22","author":"Ferrante","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.brainres.2018.06.009_b0105","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.neuron.2009.11.020","article-title":"Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice","volume":"64","author":"Gu","year":"2009","journal-title":"Neuron"},{"key":"10.1016\/j.brainres.2018.06.009_b0110","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.bcp.2013.12.023","article-title":"Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins","volume":"88","author":"Guerrero-Munoz","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.brainres.2018.06.009_b0115","doi-asserted-by":"crossref","unstructured":"Hacker, H., Karin, M., 2006. Regulation and function of IKK and IKK-related kinases. Sci. STKE, 2006, re13.","DOI":"10.1126\/stke.3572006re13"},{"key":"10.1016\/j.brainres.2018.06.009_b0120","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/hmg\/ddl013","article-title":"Regional and cellular gene expression changes in human Huntington\u2019s disease brain","volume":"15","author":"Hodges","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.brainres.2018.06.009_b0125","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/hmg\/ddt036","article-title":"A critical role of astrocyte-mediated nuclear factor-kappaB-dependent inflammation in Huntington\u2019s disease","volume":"22","author":"Hsiao","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.brainres.2018.06.009_b0130","article-title":"Huntington\u2019s disease: mechanisms of pathogenesis and therapeutic strategies","author":"Jimenez-Sanchez","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.brainres.2018.06.009_b0135","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1084\/jem.20051900","article-title":"Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors","volume":"203","author":"Kaneko","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.brainres.2018.06.009_b0140","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1750-1326-2-18","article-title":"Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers","volume":"2","author":"Kayed","year":"2007","journal-title":"Mol. Neurodegener."},{"issue":"Suppl. 1","key":"10.1016\/j.brainres.2018.06.009_b0145","first-page":"S67","article-title":"Molecular mechanisms of amyloid oligomers toxicity","volume":"33","author":"Kayed","year":"2013","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.brainres.2018.06.009_b0150","doi-asserted-by":"crossref","first-page":"7999","DOI":"10.1523\/JNEUROSCI.2675-04.2004","article-title":"Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity","volume":"24","author":"Khoshnan","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.brainres.2018.06.009_b0155","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.nbd.2011.04.015","article-title":"The role of IkappaB kinase complex in the neurobiology of Huntington\u2019s disease","volume":"43","author":"Khoshnan","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.brainres.2018.06.009_b0160","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3233\/JHD-160205","article-title":"Oxidative stress and Huntington\u2019s disease: the good, the bad, and the ugly","volume":"5","author":"Kumar","year":"2016","journal-title":"J. Huntingtons Dis."},{"key":"10.1016\/j.brainres.2018.06.009_b0165","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.tibs.2013.05.003","article-title":"Huntington\u2019s disease: underlying molecular mechanisms and emerging concepts","volume":"38","author":"Labbadia","year":"2013","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.brainres.2018.06.009_b0170","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nrneurol.2014.253","article-title":"Intravenous immunoglobulin in neurology\u2013mode of action and clinical efficacy","volume":"11","author":"Lunemann","year":"2015","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.brainres.2018.06.009_b0175","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.nbd.2009.05.007","article-title":"Systematic behavioral evaluation of Huntington\u2019s disease transgenic and knock-in mouse models","volume":"35","author":"Menalled","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.brainres.2018.06.009_b0180","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00702-010-0430-7","article-title":"Neuroinflammation in Huntington\u2019s disease","volume":"117","author":"Moller","year":"2010","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.brainres.2018.06.009_b0185","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/icb.2009.36","article-title":"Intravenous immunoglobulin up-regulates the expression of the inhibitory FcgammaIIB receptor on B cells","volume":"87","author":"Nikolova","year":"2009","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.brainres.2018.06.009_b0190","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2249.2010.04214.x","article-title":"Specific antibodies to soluble alpha-synuclein conformations in intravenous immunoglobulin preparations","volume":"161","author":"Patrias","year":"2010","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.brainres.2018.06.009_b0195","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1212\/01.wnl.0000222734.56412.17","article-title":"Microglial activation correlates with severity in Huntington disease: a clinical and PET study","volume":"66","author":"Pavese","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.brainres.2018.06.009_b0200","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1074\/mcp.M500090-MCP200","article-title":"Proteomic analysis of protein expression and oxidative modification in r6\/2 transgenic mice: a model of Huntington disease","volume":"4","author":"Perluigi","year":"2005","journal-title":"Mol. Cell. Proteomics"},{"issue":"Suppl. 3","key":"10.1016\/j.brainres.2018.06.009_b0205","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.3233\/JAD-132738","article-title":"Apoptosis and oxidative stress in neurodegenerative diseases","volume":"42","author":"Radi","year":"2014","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.brainres.2018.06.009_b0210","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.neuroscience.2011.08.052","article-title":"Pathophysiology of Huntington\u2019s disease: time-dependent alterations in synaptic and receptor function","volume":"198","author":"Raymond","year":"2011","journal-title":"Neuroscience"},{"issue":"Suppl. 1","key":"10.1016\/j.brainres.2018.06.009_b0215","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1007\/s10875-014-0041-4","article-title":"Clinical trials of intravenous immunoglobulin for Alzheimer\u2019s disease","volume":"34","author":"Relkin","year":"2014","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.brainres.2018.06.009_b0220","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1212\/WNL.0000000000000187","article-title":"PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease","volume":"82","author":"Rosas","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.brainres.2018.06.009_b0225","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1172\/JCI83185","article-title":"Targeting CAG repeat RNAs reduces Huntington\u2019s disease phenotype independently of huntingtin levels","volume":"126","author":"Rue","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.brainres.2018.06.009_b0230","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1073\/pnas.1221891110","article-title":"Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease","volume":"110","author":"Sathasivam","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.brainres.2018.06.009_b0235","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(14)61010-2","article-title":"Slowing of neurodegeneration in Parkinson\u2019s disease and Huntington\u2019s disease: future therapeutic perspectives","volume":"384","author":"Schapira","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.brainres.2018.06.009_b0240","doi-asserted-by":"crossref","DOI":"10.1093\/hmg\/ddw316","article-title":"A small molecule p75NTR ligand normalizes signalling and reduces Huntington's disease phenotypes in R6\/2 and BACHD mice","author":"Simmons","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.brainres.2018.06.009_b0245","first-page":"4920","article-title":"A small molecule p75NTR ligand normalizes signalling and reduces Huntington's disease phenotypes in R6\/2 and BACHD mice","volume":"25","author":"Simmons","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.brainres.2018.06.009_b0250","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1006\/exnr.1999.7170","article-title":"Increased complement biosynthesis by microglia and complement activation on neurons in Huntington\u2019s disease","volume":"159","author":"Singhrao","year":"1999","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.brainres.2018.06.009_b0255","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.intimp.2012.09.007","article-title":"Effects of intravenous immunoglobulin on alpha synuclein aggregation and neurotoxicity","volume":"14","author":"Smith","year":"2012","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.brainres.2018.06.009_b0260","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.freeradbiomed.2008.05.014","article-title":"Proteomic and oxidative stress analysis in human brain samples of Huntington disease","volume":"45","author":"Sorolla","year":"2008","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.brainres.2018.06.009_b0265","doi-asserted-by":"crossref","first-page":"4788","DOI":"10.1073\/pnas.0807319106","article-title":"Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy","volume":"106","author":"Tackenberg","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.brainres.2018.06.009_b0270","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/brain\/awt355","article-title":"HTT-lowering reverses Huntington\u2019s disease immune dysfunction caused by NFkappaB pathway dysregulation","volume":"137","author":"Trager","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.brainres.2018.06.009_b0275","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.nut.2003.10.007","article-title":"Assessment of the nutrition status of patients with Huntington\u2019s disease","volume":"20","author":"Trejo","year":"2004","journal-title":"Nutrition"},{"key":"10.1016\/j.brainres.2018.06.009_b0280","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1093\/hmg\/ddn175","article-title":"Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington\u2019s disease","volume":"17","author":"Wang","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.brainres.2018.06.009_b0285","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nm.3514","article-title":"Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington\u2019s disease","volume":"20","author":"Wang","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.brainres.2018.06.009_b0290","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.neuropharm.2016.02.015","article-title":"Naturally occurring autoantibodies against Abeta oligomers exhibited more beneficial effects in the treatment of mouse model of Alzheimer\u2019s disease than intravenous immunoglobulin","volume":"105","author":"Wang","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.brainres.2018.06.009_b0295","doi-asserted-by":"crossref","first-page":"36631","DOI":"10.1038\/srep36631","article-title":"A scFv antibody targeting common oligomeric epitope has potential for treating several amyloidoses","volume":"6","author":"Zha","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.brainres.2018.06.009_b0300","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1097-2765(00)80066-0","article-title":"Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP\/p300","volume":"1","author":"Zhong","year":"1998","journal-title":"Mol. Cell"}],"container-title":["Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006899318303366?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006899318303366?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,19]],"date-time":"2019-10-19T09:03:07Z","timestamp":1571475787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006899318303366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":60,"alternative-id":["S0006899318303366"],"URL":"https:\/\/doi.org\/10.1016\/j.brainres.2018.06.009","relation":{},"ISSN":["0006-8993"],"issn-type":[{"value":"0006-8993","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravenous immunoglobulin ameliorates motor and cognitive deficits and neuropathology in R6\/2 mouse model of Huntington\u2019s disease by decreasing mutant huntingtin protein level and normalizing NF-\u03baB signaling pathway","name":"articletitle","label":"Article Title"},{"value":"Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brainres.2018.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}